Biologic Dupilumab Shows Sustained Benefit in Asthma Patients

(MedPage Today) -- NASHVILLE, Tenn. -- Treatment with the biologic dupilumab (Dupixent) was associated with sustained reductions in oral corticosteroid (OCS) use in asthma patients who required both low and high daily OCS doses at baseline, according...
Source: MedPage Today Allergy - Category: Allergy & Immunology Source Type: news